Provention Bio Announces the Grant of Inducement Awards
Provention Bio, Inc. (Nasdaq: PRVB) announced the grant of stock options to 58 non-executive employees, totaling 763,000 shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Provention Bio, Inc. (Nasdaq: PRVB) announced the grant of stock options to 58 non-executive employees, totaling 763,000 shares. The options, which were issued without stockholder approval and approved by the compensation committee, have a 10-year term with an exercise price of $9.67. Options will vest 25% annually and 75% in equal monthly installments over four years, contingent on continued employment. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and is part of the company's strategy to attract and retain talent.
Positive
- Granting of stock options demonstrates proactive employee retention strategy.
- Stock options issued at $9.67 could incentivize employee performance aligning with company goals.
Negative
- None.
Details
News Market Reaction – PRVB
The recorded move for PRVB in the trading session of this news was -5.05%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RED BANK, N.J., January 6, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to 58 non-executive employees to purchase an aggregate of 763,000 shares of common stock. The stock options were granted without stockholder approval as inducements, material to the new non-executive employees entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4) and were approved by the Company's compensation committee of the board of directors.
The stock options were granted with a 10-year term and an exercise price equal to
Provention Bio, Inc. (Nasdaq: PRVB) is a commercial-stage biopharmaceutical company focused on advancing the development and commercialization of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases. The Company's pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including T1D, celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.
Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.
Investor Contact:
Kristen Kelleher, Manager, Investor Relations
investorrelations@proventionbio.com
Media Contact:
Kaelan Hollon, VP, Corporate Communications
khollon@proventionbio.com
202-421-4921
View original content to download multimedia:https://www.prnewswire.com/news-releases/provention-bio-announces-the-grant-of-inducement-awards-301714373.html
SOURCE Provention Bio, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.